
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. demonstrates a positive outlook due to its promising clinical results for PMN310, which has shown favorable safety profiles and pharmacokinetics in Phase 1a testing, supporting its progression towards further clinical development. Additionally, the advancements in PMN267 highlight its selective targeting capabilities, which could lead to significant disease-modifying activity and safety enhancements across various neurodegenerative diseases. The absence of adverse reactions associated with competing therapies and the robust in vitro validation underpin the company's potential for growth and the likelihood of achieving meaningful clinical milestones.
Bears say
ProMIS Neurosciences has reported a significant net loss of $11.6 million, or $0.24 per share, for the third quarter of 2025, reflecting ongoing financial struggles with no history of profitability. The company faces potential challenges that may hinder its operational success, including the risks of future partnerships, competition that may slow market uptake, and concerns regarding near-term dilution. Additionally, emerging scientific evidence suggests that the company’s focus on targeting toxic Aβ oligomers could be undermined by previously failed therapies, raising doubts about the efficacy of its proposed solutions in treating neurodegenerative diseases.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares